ArticleInternational journal of molecular sciences2026
MCOF: A Multi-Channel Attention-Based Omics Fusion Framework for Cancer Subtyping and Candidate Biomarker Prioritization.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Multi-omics molecular subtyping is complicated by small cohorts, heterogeneous data layers, and sensitivity to data splitting and feature selection. We developed multi-channel attention-based omics fusion (MCOF), an end-to-end framework that combines omics-specific projection, one-dimensional convolution, and integrated gradients for candidate biomarker prioritization. MCOF was evaluated against six baselines using five repeated stratified holdouts across four multi-omics datasets. In the restricted four-class breast invasive carcinoma task, MCOF achieved the highest observed mean for all five metrics, including an accuracy of 0.900 ± 0.022 and a macro-averaged area under the receiver operating characteristic curve (macro-AUC) of 0.982 ± 0.003. In the restricted three-class stomach adenocarcinoma task, it achieved the highest observed macro-F1 (0.786 ± 0.035), macro-AUC (0.934 ± 0.020), and weighted-AUC (0.930 ± 0.016), whereas support vector machines had a slightly higher accuracy and weighted F1. It also achieved the highest or near-highest AUC on the two non-cancer datasets. Compared with MOGONET, MCOF used 30.6% fewer trainable parameters on both cancer tasks. Sensitivity analyses indicated that the contribution of multi-omics fusion varied by dataset and metric. Excluding the 28 prediction analysis of microarray 50 (PAM50) genes present in the retained BRCA RNA panel produced only a modest reduction in the macro-AUC, from 0.982 ± 0.003 to 0.978 ± 0.004. Implementation tests across 20 trained checkpoints detected no batch-order effect or cross-sample gradient, while the IG rankings were moderately stable across repeated holdouts and numerically consistent across class-weighting schemes and 25-100 integration steps. MCOF provides a practical framework for multi-omics classification and candidate prioritization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.